Skip to main content

Table 6 Skin toxicity criteria for dose delay and dose modification of sorafenib

From: Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study

Toxicity Grade

During a Course of Therapy

Dose for Next Cycle

Grade 1

 

Maintain dose level#

Maintain dose level

Grade 2

1st appearance

Interrupt until resolved to grade 0-1

Maintain dose level

 

2nd appearance

Interrupt until resolved to grade 0-1

400 mg every day

 

3rd appearance

Interrupt until resolved to grade 0-1

400 mg every the other day

 

4th appearance

Discontinue treatment permanently

 

Grade 3

1st appearance

Interrupt until resolved to grade 0-1

400 mg every day

 

2nd appearance

Interrupt until resolved to grade 0-1

400 mg every the other day

 

3rd appearance

Discontinue treatment permanently

Â